Trial Profile
A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Subjects Undergoing Surgery for Congenital Heart Defects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Feb 2023
Price :
$35
*
At a glance
- Drugs Citrulline (Primary)
- Indications Acute lung injury
- Focus Registrational; Therapeutic Use
- Sponsors Asklepion Pharmaceuticals
- 06 Jan 2020 Status changed from active, no longer recruiting to completed.
- 05 Sep 2019 This trial has been completed in Austria, Germany
- 01 Jul 2019 According to an Asklepion Pharmaceuticals media release, the results of the trial are expected in October 2019.